Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board ...
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Congress missed a chance at PBM reforms.
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...